Navigation Links
Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
Date:11/5/2008

PRINCETON, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the completion of a Phase 2 trial of CNTO 95, a fully human antibody targeting the integrin receptors that are implicated in tumor-induced angiogenesis. The CNTO 95 human antibody was generated using Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.

"We are pleased with the progress of this program and the potential of technology licensing programs under our partnership with Centocor to contribute to future revenues," said Howard H. Pien, President and CEO of Medarex.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "may" or "potential" or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include those risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
2. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
3. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
4. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
5. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
8. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
9. Medarex Announces Ipilimumab Program Continues to Move Forward
10. Medarex to Receive Milestone Payment from Amgen
11. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... According to a study conducted by Persistence Market Research (PMR), ... of 6.5% during the forecast period 2016-2024. According to the study, ... leading market for cryotherapy globally during the forecast period  ... Highlights from the Report  ... supply of gas in order to provide smoother maintenance services to ...
(Date:1/19/2017)... Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... analysis instruments and consumables for the medical and veterinary ... its financial results for the third quarter fiscal year ... at 4:15 p.m. ET on Thursday, January 26, 2017.  ... quarter fiscal year 2017 after the market closes on ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out ... trade show to continue the marketing and distribution of its product, The Right C. ... 400 percent better absorption than traditional vitamin C supplements. At the trade show, Doctor ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... ... January 20, 2017 , ... D ... Expiratory Pressure (OPEP) device, was featured in a study indicating superior performance against ... FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
Breaking Medicine News(10 mins):